이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Smoking Cessation With Wearables to Improve General, Oral Health and Quality of Life (Wear-Smile)

2026년 5월 11일 업데이트: Alessia Bramanti, University of Salerno

Smoking Cessation Programme in Telerehabilitation Assisted by Telemonitoring With Non-Invasive Wearable Devices for the Improvement of Oral Health, General Health and Quality of Life

Tobacco smoking remains one of the leading preventable causes of disease, disability, and premature death worldwide. According to the World Health Organization, tobacco use is responsible for more than eight million deaths each year globally, including deaths caused by direct smoking and exposure to secondhand smoke. Smoking is a major risk factor for a wide range of chronic diseases, including cardiovascular diseases, chronic respiratory diseases, several types of cancer, and numerous oral health conditions. In addition to systemic effects, tobacco use is strongly associated with oral potentially malignant disorders and oral squamous cell carcinoma, representing a significant burden for public health systems.

Despite the well-documented health risks, smoking cessation remains difficult for many individuals due to the addictive properties of nicotine and the complex behavioral and psychological components associated with tobacco dependence. Multimodal smoking cessation programs that combine behavioral counseling, psychological support, and continuous monitoring have been shown to increase the likelihood of successful cessation. However, access to these programs may be limited by logistical barriers, including geographic distance, time constraints, and limited availability of specialized services.

In recent years, telemedicine and digital health technologies have emerged as promising tools to support healthcare delivery and improve access to treatment programs. Telemedicine platforms allow remote interaction between patients and healthcare professionals, facilitating communication, follow-up, and monitoring of patients over time. Additionally, wearable devices and remote monitoring systems enable the collection of physiological and behavioral data outside traditional clinical settings, providing clinicians with valuable information to support personalized interventions.

The aim of this study is to evaluate the effectiveness and feasibility of a smoking cessation program delivered through a telerehabilitation model supported by an integrated telemedicine platform and wearable remote monitoring devices. The program is designed to support individuals who smoke tobacco products, including both combustible tobacco and alternative nicotine-containing products, by providing behavioral and psychological interventions combined with continuous remote monitoring.

Participants enrolled in the study will be assigned to one of two groups. The intervention group will participate in a telerehabilitation program delivered through a dedicated telemedicine platform. This program will include structured behavioral and psychological treatment sessions aimed at supporting smoking cessation, along with remote monitoring through non-invasive wearable devices that allow healthcare professionals to track selected physiological parameters and patient engagement during the treatment process.

The control group will receive the same multimodal behavioral and psychological treatment program but delivered through conventional rehabilitation methods without the use of telemedicine technologies or wearable monitoring devices.

By comparing these two approaches, the study aims to explore whether the integration of telemedicine and wearable technologies into smoking cessation programs may improve patient engagement, facilitate monitoring, and potentially enhance the effectiveness of behavioral interventions aimed at reducing tobacco use. The findings of this study may contribute to the development of innovative digital health strategies for smoking cessation and provide evidence to support the integration of telemedicine into addiction treatment and preventive healthcare programs.

연구 개요

상세 설명

Tobacco smoking continues to represent one of the most significant and preventable causes of morbidity and mortality worldwide. According to the World Health Organization, tobacco use is responsible for more than eight million deaths every year globally, including deaths caused by direct smoking and those attributable to exposure to secondhand smoke. Tobacco consumption is associated with a wide range of chronic diseases that affect multiple organ systems, including cardiovascular diseases, respiratory disorders, metabolic conditions, and numerous forms of cancer. As a result, smoking represents a major public health concern and a substantial burden for healthcare systems worldwide.

The negative health effects of tobacco use extend beyond systemic diseases and include important implications for oral health. Smoking is strongly associated with oral inflammatory diseases, periodontal disease, delayed wound healing, and a significantly increased risk of oral potentially malignant disorders and oral squamous cell carcinoma. For these reasons, smoking cessation plays a critical role in both preventive medicine and oral healthcare. Promoting effective strategies to support smoking cessation is therefore a priority for public health initiatives and clinical practice.

Despite the well-documented health risks associated with tobacco use, many individuals continue to smoke due to the addictive properties of nicotine and the complex psychological, behavioral, and social factors involved in tobacco dependence. Nicotine addiction is characterized by both physiological dependence and behavioral reinforcement mechanisms that make quitting smoking particularly challenging. Many smokers attempt to quit multiple times before achieving long-term abstinence, and relapse rates remain high without structured support.

Evidence suggests that smoking cessation interventions are more effective when they combine multiple treatment components. Multimodal approaches that include behavioral counseling, psychological support, motivational strategies, and continuous monitoring have been shown to increase the probability of successful smoking cessation compared with minimal interventions or self-directed attempts to quit. However, access to structured smoking cessation programs remains limited in many contexts due to barriers such as geographic distance, time constraints, lack of specialized services, and difficulties maintaining long-term follow-up.

In recent years, telemedicine and digital health technologies have emerged as promising tools to improve the accessibility, continuity, and effectiveness of healthcare interventions. Telemedicine refers to the delivery of healthcare services through digital communication technologies that allow remote interaction between patients and healthcare professionals. Telemedicine platforms can facilitate clinical consultations, follow-up visits, behavioral counseling, and patient monitoring without requiring in-person attendance at healthcare facilities.

The use of telemedicine in behavioral health interventions has expanded significantly in recent years, particularly following the global COVID-19 pandemic, which accelerated the adoption of remote healthcare services. Telehealth approaches have demonstrated potential benefits in terms of improving access to care, reducing logistical barriers, and maintaining continuity of treatment for patients who may otherwise face difficulties attending traditional clinical appointments.

In addition to telecommunication technologies, wearable monitoring devices have become increasingly important tools in digital health. Wearable devices are capable of collecting physiological and behavioral data in real time, allowing healthcare professionals to remotely monitor various parameters such as physical activity, heart rate, sleep patterns, and other health indicators. The integration of wearable monitoring systems into telemedicine platforms may further enhance the capacity to provide personalized and continuous care.

Within the context of smoking cessation programs, remote monitoring technologies may support clinicians in evaluating patient engagement, monitoring behavioral changes, and identifying potential challenges during the cessation process. Continuous monitoring and regular communication between patients and healthcare professionals may help improve adherence to treatment protocols and provide timely support when needed.

The present study aims to investigate the feasibility and effectiveness of a smoking cessation program delivered through a telerehabilitation model supported by an integrated telemedicine platform and wearable remote monitoring devices. Telerehabilitation refers to the remote delivery of rehabilitation services using digital communication technologies and remote monitoring systems. This approach allows healthcare professionals to provide structured treatment programs while maintaining continuous contact with patients in their everyday environments.

Participants eligible for the study will include adult individuals who smoke tobacco products, including both combustible tobacco and alternative nicotine-containing products. Eligible participants will be recruited and assigned to one of two study groups.

Participants in the intervention group will take part in a telerehabilitation-based smoking cessation program delivered through an integrated telemedicine platform. The intervention will include multimodal behavioral and psychological treatment designed to support smoking cessation through structured counseling sessions, motivational strategies, and continuous monitoring. Participants in this group will also use non-invasive wearable monitoring devices that enable healthcare professionals to remotely collect selected physiological and behavioral data during the treatment process. These devices will allow clinicians to monitor patient engagement and support individualized follow-up throughout the program.

Participants assigned to the control group will receive the same multimodal behavioral and psychological smoking cessation program delivered through conventional rehabilitation methods. In this case, treatment will be provided without the support of telemedicine platforms or wearable monitoring technologies. The control group therefore represents the standard rehabilitation approach typically used in clinical practice.

By comparing these two groups, the study aims to evaluate whether the integration of telemedicine technologies and wearable monitoring devices into smoking cessation programs may improve treatment delivery, enhance patient engagement, and support better monitoring during the rehabilitation process. The study will also explore the feasibility of implementing telerehabilitation approaches in the context of smoking cessation and behavioral health interventions.

The results of this study may contribute to the growing body of evidence supporting the use of digital health technologies in addiction treatment and preventive healthcare. Furthermore, the findings may provide valuable insights for the development of scalable and accessible smoking cessation programs that can be implemented in different healthcare settings, helping to expand access to effective interventions for individuals seeking to quit tobacco use.

연구 유형

중재적

등록 (추정된)

102

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Alessia Bramanti, Associate Professor
  • 전화번호: +393483809181
  • 이메일: abramanti@unisa.it

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  • Subjects who smoke ≥ 5 cigarettes per day (traditional or equivalent in nicotine content in non-combustible tobacco or liquid/vape), regardless of the severity of nicotine dependence
  • Subjects ≥ 18 years of age
  • Ability and willingness to provide informed consent or presence of a legal representative who consents
  • Subjects in possession of home medical devices for measuring cardiopulmonary parameters (sphygmomanometer and pulse oximeter) (requirement applicable to participants assigned to the control group)

Exclusion Criteria:

  • Age < 18
  • Pregnant or breastfeeding women
  • Subjects with a remote or current history of using smoking cessation methods
  • Subjects with acute dependence on alcohol or other substances of abuse other than nicotine
  • Pathologies with advanced neurocognitive degeneration
  • Unstable psychiatric conditions (subjects with active suicidal ideation, hospitalization for psychiatric reasons and/or changes in psychiatric medication for less than 3 months)
  • Inability or refusal to sign informed consent
  • Inability to access the integrated telemedicine platform and/or wearable remote monitoring devices (requirement applicable to participants assigned to the experimental group)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 지지 요법
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Telerehabilitation Smoking Cessation Program
Subjects who smoke tobacco with and without combustion and products containing nicotine in telerehabilitation. Assisted, monitored and undergoing multimodal treatment (behavioural-psychological treatment) with the aid of an integrated telemedicine platform and wearable remote monitoring devices.
Participants receive a personalized multimodal behavioral and psychological smoking cessation intervention delivered through a telemedicine platform. The intervention includes individual counseling, cognitive behavioral therapy, and motivational support provided remotely. The telemedicine system is web-based and accessible from computers or mobile devices (Android or iOS). Participants may also use non-invasive wearable devices integrated with the telemedicine platform to remotely monitor vital parameters, including heart rate, blood pressure, respiratory rate, and oxygen saturation, measured twice daily for up to 12 months. Smoking behavior is recorded using a standardized smoking diary. The telemedicine platform allows clinicians to monitor participants' progress and conduct teleconsultations when needed.
활성 비교기: Conventional Rehabilitation Smoking Cessation Program
Subjects who smoke combustible and non-combustible tobacco and nicotine-containing products in conventional rehabilitation. Assisted, monitored and undergoing multimodal behavioural-psychological treatment (similar to the study group) without the aid of an integrated telemedicine platform and wearable remote monitoring devices.
Participants receive a personalized multimodal behavioral and psychological smoking cessation intervention delivered through conventional in-person clinical care according to national clinical guidelines. The intervention includes individual counseling, cognitive behavioral therapy, and motivational support provided during face-to-face visits. Follow-up sessions are scheduled two weeks after the initial consultation and then monthly for up to 12 months to support smoking cessation and prevent relapse. Participants record smoking behavior using a standardized smoking diary and monitor cardiopulmonary parameters at home using portable medical devices.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Continuous Abstinence Rate (CAR) from tobacco and nicotine-containing products
기간: 6 months and 12 months after baseline
Continuous abstinence rate (CAR) defined as the proportion (%) of participants who remain completely abstinent from combustible and non-combustible tobacco and nicotine-containing products from the start of the cessation program to the follow-up assessment at 6 and 12 months. Abstinence will be assessed through participant self-report using a standardized smoking diary.
6 months and 12 months after baseline
Point Prevalence Abstinence (PPA)
기간: 6 months and 12 months after baseline
Point prevalence abstinence (PPA) defined as the proportion (%) of participants reporting no use of combustible or non-combustible tobacco products at the time of follow-up assessment.
6 months and 12 months after baseline

2차 결과 측정

결과 측정
측정값 설명
기간
Heart rate
기간: Daily monitoring and evaluation at 6 and 12 months
Changes in heart rate (beats per minute, bpm) measured through wearable monitoring devices (telerehabilitation group) or home medical devices (control group).
Daily monitoring and evaluation at 6 and 12 months
Blood pressure
기간: Daily monitoring and evaluation at 6 and 12 months.
Changes in blood pressure (millimeters of mercury, mmHg) measured through wearable monitoring devices (telerehabilitation group) or home medical devices (control group).
Daily monitoring and evaluation at 6 and 12 months.
Respiratory rate
기간: Daily monitoring and evaluation at 6 and 12 months.
Changes in respiratory rate (breaths/minute) measured through wearable monitoring devices (telerehabilitation group) or home medical devices (control group).
Daily monitoring and evaluation at 6 and 12 months.
Oxygen Saturation
기간: Daily monitoring and evaluation at 6 and 12 months.
Changes in oxygen saturation (SpO₂, %), measured through wearable monitoring devices (telerehabilitation group) or home medical devices (control group).
Daily monitoring and evaluation at 6 and 12 months.
Probing depth
기간: Baseline, 6 months, and 12 months
Changes in periodontal probing depth (millimeters, mm), measured during standardized dental examinations.
Baseline, 6 months, and 12 months
Full-mouth bleeding index
기간: Baseline, 6 months, and 12 months.
Changes in full-mouth bleeding index, expressed as the percentage (%) of bleeding sites, measured during standardized dental examinations. Higher percentages indicate worse periodontal status.
Baseline, 6 months, and 12 months.
Full-mouth plaque index
기간: Baseline, 6 months, and 12 months.
Changes in full-mouth plaque index (%) of plaque-positive sites, measured during standardized dental examinations. Higher percentages indicate worse oral hygiene status.
Baseline, 6 months, and 12 months.
Oral health related quality of life
기간: Baseline, 6 months, and 12 months
Oral health-related quality of life measured using the Oral Health Impact Profile (OHIP-14). Scores range from 0 to 56, with higher scores indicating worse oral health-related quality of life.
Baseline, 6 months, and 12 months
Health-related quality of life
기간: Baseline, 6 months, and 12 months
Health-related quality of life measured using the Short Form Health Survey (SF-36). Scores range from 0 to 100, with higher scores indicating better health-related quality of life.
Baseline, 6 months, and 12 months

기타 결과 측정

결과 측정
측정값 설명
기간
Nicotine dependence severity
기간: Baseline, 6 months, and 12 months
Nicotine dependence measured using the Fagerström Test for Nicotine Dependence (FTND). FTND scores range from 0 to 10, with higher scores indicating greater nicotine dependence.
Baseline, 6 months, and 12 months
Usability
기간: 6 months and 12 months
Usability with the smoking cessation program will be assessed using the System Usability Scale (SUS). SUS scores range from 0 to 100, with higher scores indicating better usability.
6 months and 12 months
Acceptability
기간: 6 months and 12 months
Acceptability with the smoking cessation program will be assessed using the Treatment Acceptability/Adherence Scale (TAAS). TAAS scores range from 10 to 70, with higher scores indicating better acceptability.
6 months and 12 months
Patient and Doctor Satisfaction
기간: 6 months and 12 months
Satisfaction with the smoking cessation program will be assessed using the Client Satisfaction Questionnaire (CSQ-8). CSQ-8 scores range from 8 to 32, with higher scores indicating greater satisfaction.
6 months and 12 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 6월 1일

기본 완료 (추정된)

2026년 12월 31일

연구 완료 (추정된)

2027년 11월 1일

연구 등록 날짜

최초 제출

2026년 3월 9일

QC 기준을 충족하는 최초 제출

2026년 5월 11일

처음 게시됨 (실제)

2026년 5월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 5월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 5월 11일

마지막으로 확인됨

2026년 1월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Individual participant data (IPD) will not be shared. Due to privacy and data protection considerations, the dataset contains sensitive health information that cannot be sufficiently de-identified without compromising participant confidentiality. Aggregate results will be reported in publications and presentations.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다